Stay updated with breaking news from ப்ரிவேல் சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biopharma M&A set for a strong H2 despite political noise—and Biogen and Gilead look like buyers: analysts fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
The Next Decade In Gene Therapy Innovation — 6 Critical Questions (And Answers) bioprocessonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bioprocessonline.com Daily Mail and Mail on Sunday newspapers.
The Next Decade In Gene Therapy Innovation â 6 Critical Questions (And Answers) By Kyle M. OâNeil and Brendan J. Wang, Back Bay Life Science Advisors As the gene therapy field has tackled delivery vectors as described in “An Analysis Of The Gene Therapy Viral Vector Landscape,” several clinical and commercial questions lowered expectations for gene therapy sales, leading sell-side forecasts to fall more than 50% since 2018. 1 However, more than $6.5 billion in 2026 projected gene therapy sales remain across Duchenne muscular dystrophy (DMD), hemophilia A/B, sickle cell disease, Fabry disease, Huntington’s disease, and Leber congenital amaurosis type 10 (LCA10) alone, putting pressure on industry-leading gene therapy companies to deliver. ....
Eli Lilly (NYSE:LLY) outperformed the broad market S&P 500 index in 2020, but its winning days are not in the rearview mirror. With its strong catalog and pipeline, growing revenues, and a recently boosted dividend, I think the pharma stalwart is still an exceptional buy. Up and down, but mostly up Eli Lilly boasts one of the more diverse catalogs in the industry, and last year boasted nine drugs that individually raked in more than $1 billion annually. Its revenue leaders were Trulicity (for type 2 diabetes), Taltz (for plaque psoriasis), and Jardiance (also for type 2 diabetes), which brought in $5.06 billion, $1.788 billion, and $1.153 billion, respectively. Each s sales grew by 23%, 31%, and 22% year over year. ....
16% Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Beginning in 2021, non-GAAP measures exclude gains and losses on investments in equity securities and 2020 amounts have been reclassified for comparability. The company s 2021 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company s business. ....